Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Plimoth Trust Co. LLC

Plimoth Trust Co. LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 7,165 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. Plimoth Trust Co. LLC’s holdings in Gilead Sciences were worth $662,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Algert Global LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at $254,000. Creative Planning raised its stake in Gilead Sciences by 8.4% during the 2nd quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company’s stock valued at $12,939,000 after purchasing an additional 14,544 shares during the period. Magnolia Capital Advisors LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at $461,000. Sunbelt Securities Inc. raised its stake in Gilead Sciences by 35.1% during the 2nd quarter. Sunbelt Securities Inc. now owns 15,678 shares of the biopharmaceutical company’s stock valued at $1,076,000 after purchasing an additional 4,075 shares during the period. Finally, Quarry LP acquired a new stake in Gilead Sciences during the 2nd quarter valued at $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD traded up $1.77 during trading on Wednesday, reaching $95.62. 755,874 shares of the company traded hands, compared to its average volume of 6,513,060. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock’s 50 day moving average price is $92.00 and its two-hundred day moving average price is $85.44. The company has a market cap of $119.16 billion, a price-to-earnings ratio of 1,062.89, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Oppenheimer boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. BMO Capital Markets upped their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 456,234 shares of company stock valued at $42,130,461. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.